Pfizer Inc. (NYSE:PFE) received FDA approval for its COVID-19 vaccine for adults 65+ and those with underlying conditions. The approval was based on safety and efficacy data, including trials for children aged 5-11. The vaccine generates improved immune responses against multiple SARS-CoV-2 sublineages.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that develops and sells biopharmaceutical products worldwide. While considered a solid investment, some AI stocks offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks should explore opportunities beyond Pfizer.

Investors should consider other AI stocks with greater potential than Pfizer (PFE). Some AI stocks offer significant upside potential and benefit from current economic trends. For more information on the best short-term AI stock, investors can access a free report. Further research on AI stocks with potential growth can also be beneficial for investors.

Read more at Yahoo Finance: Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine